132 related articles for article (PubMed ID: 38837565)
41. Treatment of refractory acute myeloid leukaemia during pregnancy with venetoclax, high-dose cytarabine and mitoxantrone.
Karagiannis P; Alsdorf W; Tallarek AC; Blohm ME; Oelrich J; Waizenegger JS; Wolschke C; Hecher K; Singer D; Bokemeyer C; Fiedler W
Br J Haematol; 2021 Jan; 192(2):e60-e63. PubMed ID: 33222152
[No Abstract] [Full Text] [Related]
42. Combination of Venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia: A case series from a single center.
Secilmis S; Sinan Dal M; Kizil Cakar M; Merdin A; Ahu Baysal N; Altuntas F
J BUON; 2021; 26(5):2026-2032. PubMed ID: 34761613
[TBL] [Abstract][Full Text] [Related]
43. Venetoclax for Refractory Myeloid Sarcoma.
Kanate AS; Vos J; Chargualaf MJ
J Oncol Pract; 2019 Jul; 15(7):413-415. PubMed ID: 31291562
[No Abstract] [Full Text] [Related]
44. Successful use of venetoclax for treatment of eosinophilic dermatosis of myeloproliferative disease in a patient with chronic lymphocytic leukemia.
Peringeth G; Sundaram S; Bogner P; Conroy E; Torka P
Ann Hematol; 2020 May; 99(5):1129-1131. PubMed ID: 32193627
[No Abstract] [Full Text] [Related]
45. Co-operation of ABT-199 and gemcitabine in impeding DNA damage repair and inducing cell apoptosis for synergistic therapy of T-cell acute lymphoblastic leukemia.
Xiufeng Z; Haijun Z; Silei B; Manman D; Yong Z; Lian Y; Zhihong F; Bing X
Anticancer Drugs; 2019 Feb; 30(2):138-148. PubMed ID: 30320607
[TBL] [Abstract][Full Text] [Related]
46. Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies.
King AC; Peterson TJ; Horvat TZ; Rodriguez M; Tang LA
Ann Pharmacother; 2017 May; 51(5):410-416. PubMed ID: 28056525
[TBL] [Abstract][Full Text] [Related]
47. Activity of venetoclax-based therapy in chronic myelomonocytic leukemia.
Montalban-Bravo G; Hammond D; DiNardo CD; Konopleva M; Borthakur G; Short NJ; Ramos-Perez J; Guerra V; Kanagal-Shamanna R; Naqvi K; Sasaki K; Jabbour E; Pemmaraju N; Kadia TM; Ravandi F; Daver N; Estrov Z; Pierce S; Kantarjian H; Garcia-Manero G
Leukemia; 2021 May; 35(5):1494-1499. PubMed ID: 33846541
[No Abstract] [Full Text] [Related]
48. T cell ALL in a child with Ataxia telangiectasia; diagnosis and management challenges.
Ahmed O; Felimban Y; Almehdar A
Hematology; 2021 Dec; 26(1):348-354. PubMed ID: 33843495
[TBL] [Abstract][Full Text] [Related]
49. Venetoclax active and safe in non-Hodgkin lymphoma.
Das M
Lancet Oncol; 2017 Mar; 18(3):e136. PubMed ID: 28139404
[No Abstract] [Full Text] [Related]
50. Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia.
Rogers KA; Huang Y; Ruppert AS; Awan FT; Heerema NA; Hoffman C; Lozanski G; Maddocks KJ; Moran ME; Reid MA; Lucas M; Woyach JA; Whitlow WT; Jones JA; Byrd JC
Blood; 2018 Oct; 132(15):1568-1572. PubMed ID: 30111609
[TBL] [Abstract][Full Text] [Related]
51. Venetoclax plus hypomethylating agents or low-dose cytarabine in acute myeloid leukemia: all that glitters is gold?
Ferrara F
Blood Cancer J; 2020 Jan; 10(1):10. PubMed ID: 31992691
[No Abstract] [Full Text] [Related]
52. Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway.
Lonetti A; Cappellini A; Bertaina A; Locatelli F; Pession A; Buontempo F; Evangelisti C; Evangelisti C; Orsini E; Zambonin L; Neri LM; Martelli AM; Chiarini F
J Hematol Oncol; 2016 Oct; 9(1):114. PubMed ID: 27776559
[TBL] [Abstract][Full Text] [Related]
53. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
[TBL] [Abstract][Full Text] [Related]
54. Venetoclax and dexamethasone synergize with inotuzumab ozogamicin-induced DNA damage signaling in B-lineage ALL.
Kirchhoff H; Karsli U; Schoenherr C; Battmer K; Erschow S; Talbot SR; Steinemann D; Heuser M; Heidenreich O; Hilfiker-Kleiner D; Ganser A; Eder M; Scherr M
Blood; 2021 May; 137(19):2657-2661. PubMed ID: 33512436
[TBL] [Abstract][Full Text] [Related]
55. The Emerging Role of Venetoclax-Based Treatments in Acute Lymphoblastic Leukemia.
Aumann S; Shaulov A; Haran A; Gross Even-Zohar N; Vainstein V; Nachmias B
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142863
[TBL] [Abstract][Full Text] [Related]
56. Fatal tumor lysis syndrome in a pediatric patient with acute lymphoblastic leukemia treated with venetoclax.
Trinder SM; Soggee J; Spragg J; Alexander D; Mitchell R; Gottardo NG; Ramachandran S
Pediatr Blood Cancer; 2024 Mar; 71(3):e30841. PubMed ID: 38149837
[No Abstract] [Full Text] [Related]
57. Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation.
Joshi M; Cook J; McCullough K; Nanaa A; Gangat N; Foran JM; Murthy HS; Kharfan-Dabaja MA; Sproat L; Palmer J; Pardanani A; Tefferi A; Begna K; Elliot M; Al-Kali A; Patnaik M; Shah MV; Hogan WJ; Litzow MR; Alkhateeb HB
Blood Cancer J; 2021 Mar; 11(3):49. PubMed ID: 33664234
[No Abstract] [Full Text] [Related]
58. Double remission of simultaneously occurring secondary AML and CLL by venetoclax monotherapy.
Niscola P; Noguera NI; Catalano G; Cupelli L; Fratoni S; Giovannini M; Mazzone C; Neri B; Scaramucci L; Trawinska MM; de Fabritiis P; Abruzzese E
Acta Oncol; 2019 Jun; 58(6):888-890. PubMed ID: 30848978
[No Abstract] [Full Text] [Related]
59. Outcomes of venetoclax-based therapy in chronic phase and blast transformed chronic myelomonocytic leukemia.
Saliba AN; Litzow MR; Gangat N; Al-Kali A; Foran JM; Hogan WJ; Palmer JM; Mangaonkar AA; Tefferi A; Patnaik MM
Am J Hematol; 2021 Nov; 96(11):E433-E436. PubMed ID: 34428328
[No Abstract] [Full Text] [Related]
60. Response assessment to venetoclax in relapsed/refractory chronic lymphocytic leukemia by ultrasonography.
Benedetti E; Baratè C; Bruno B; Bramanti E; Ghia P; Scarfò L; Morganti R; Ricchiuto V; Galimberti S
Leuk Res; 2021 Jan; 100():106488. PubMed ID: 33316660
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]